Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Trial Profile

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Afatinib (Primary) ; Esomeprazole (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Acronyms The BIO-GIO study
  • Most Recent Events

    • 21 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top